Citizens National Bank Trust Department Sells 710 Shares of Medtronic plc (NYSE:MDT)

Citizens National Bank Trust Department reduced its position in shares of Medtronic plc (NYSE:MDT) by 3.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,464 shares of the medical technology company’s stock after selling 710 shares during the period. Citizens National Bank Trust Department’s holdings in Medtronic were worth $1,395,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Sequoia Financial Advisors LLC raised its stake in Medtronic by 14.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 72,228 shares of the medical technology company’s stock valued at $6,503,000 after purchasing an additional 9,340 shares during the last quarter. Signaturefd LLC raised its stake in Medtronic by 4.3% during the 3rd quarter. Signaturefd LLC now owns 13,332 shares of the medical technology company’s stock valued at $1,200,000 after purchasing an additional 551 shares during the last quarter. Eastern Bank acquired a new position in Medtronic during the 3rd quarter valued at $1,902,000. GAM Holding AG raised its stake in Medtronic by 0.4% during the 3rd quarter. GAM Holding AG now owns 109,330 shares of the medical technology company’s stock valued at $9,843,000 after purchasing an additional 440 shares during the last quarter. Finally, Meadow Creek Wealth Advisors LLC raised its stake in Medtronic by 5.9% during the 3rd quarter. Meadow Creek Wealth Advisors LLC now owns 5,677 shares of the medical technology company’s stock valued at $511,000 after purchasing an additional 318 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Insider Buying and Selling at Medtronic

In other news, EVP Brett A. Wall sold 12,437 shares of Medtronic stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $90.00, for a total transaction of $1,119,330.00. Following the completion of the sale, the executive vice president now owns 40,979 shares in the company, valued at $3,688,110. The trade was a 23.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.20% of the company’s stock.

Medtronic Trading Up 1.1 %

Shares of MDT stock opened at $87.05 on Thursday. The company has a quick ratio of 1.39, a current ratio of 1.84 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $111.62 billion, a P/E ratio of 26.46, a P/E/G ratio of 2.44 and a beta of 0.84. Medtronic plc has a 12-month low of $75.96 and a 12-month high of $93.08. The firm has a 50-day moving average price of $85.82 and a 200 day moving average price of $87.02.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.03. The firm had revenue of $8.29 billion during the quarter, compared to analysts’ expectations of $8.33 billion. Medtronic had a net margin of 12.83% and a return on equity of 14.11%. Research analysts forecast that Medtronic plc will post 5.45 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Shareholders of record on Friday, December 27th were given a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 3.22%. The ex-dividend date was Friday, December 27th. Medtronic’s payout ratio is presently 85.11%.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research note on Wednesday. Sanford C. Bernstein increased their price objective on shares of Medtronic from $96.00 to $97.00 and gave the company an “outperform” rating in a research note on Wednesday, November 20th. Wells Fargo & Company dropped their price objective on shares of Medtronic from $106.00 to $98.00 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Barclays increased their price objective on shares of Medtronic from $105.00 to $109.00 and gave the company an “overweight” rating in a research note on Tuesday, November 26th. Finally, Robert W. Baird increased their price objective on shares of Medtronic from $90.00 to $91.00 and gave the company a “neutral” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $95.20.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.